Search Results - robert+yolken

3 Results

Sort By:

Non-invasive Serological Assay to predict Toxoplasma-associated disease in at-risk populations

Unmet Need: Toxoplasmic Encephalitis (TE) is a life-threatening central nervous system (CNS) disorder that results from the reactivation of a chronic brain infection with Toxoplasma gondii. Chronic T. gondii infection poses a constant and severe danger in situations of immunodeficiency as can occur in HIV infection, organ transplantation, or cancer...

Published: 5/10/2024 | Inventor(s): Jianchun Xiao, Raphael Viscidi, Robert Yolken

Keywords(s):

Category(s): Clinical and Disease Specializations > Infectious Diseases > Toxoplasmosis, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays

Use of Sulforaphane to inhibit Coronaviruses such as SARS-CoV-2 and to treat coronavirus diseases such as COVID19

Unmet Need: COVID-19 is a worldwide problem, and infection rates continue to -increase as new variants arise . Additionally, Long COVID has emerged as a growing problem of great concern. Very few options for treatment are available for general use. Therefore, more therapies and prophylactics are urgently needed to suppress the rise of confirmed acute...

Published: 5/10/2024 | Inventor(s): Lorraine Brando, Alvaro Ordonez, Robert Yolken, Sanjay Jain

Keywords(s):

Category(s): Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities > Nutritional Compounds, Technology Classifications > Therapeutic Modalities

Use of Novel Derivatives of Artemisinin To Inhibit Toxoplasma Gondii

C05086: Use of Novel Derivatives of Artemisinin To Inhibit Toxoplasma Gondii Technical Details: Toxoplasmosis, caused by the protozoan Toxoplasma gondii, is a medically important infection that is distributed worldwide. Current treatments for the prevention and treatment of toxoplasmosis are of limited efficacy and have undesirable side-effects. According...

Published: 5/9/2024 | Inventor(s): John D'angelo, Gary Posner, Robert Yolken, Lorraine Brando

Keywords(s): Antagonists/Inhibitors, Disease Indication, Infectious Diseases, Novel, Parasitic Infections, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Toxoplasmosis

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Parasitic Infections, Clinical and Disease Specializations > Infectious Diseases > Toxoplasmosis, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities